At the University of Colorado Cancer Center, we know a cancer diagnosis can be life-changing so we have built partnerships around the state and in the cancer community to help prevent cancer, discover new treatment options and educate the public about cancer.
The Colorado State University Animal Cancer Center (ACC) is the preeminent cancer center for animals, offering the latest in diagnostics and treatment for all kinds of cancer in companion animals including surgery, chemotherapy and radiation therapy.
ACC is the largest animal cancer center in the United States and one of a few programs in the country where companion animals can receive comprehensive surgical, medical and radiation oncology therapy for cancer. In addition, ACC is active in the clinical testing of new cancer therapies and has the capacity to perform functional imaging and to obtain tumor tissue before and after treatment with targeted agents.
The Pharmacology Shared Resource is located at Colorado State University. In addition to the CU Cancer Center Pharmacology Shared Resource, the following the CU Cancer Center research programs and shared resources collaborate with ACC:
Colorado State Animal Cancer Center
Veterinary Teaching Hospital
Colorado State University
Fort Collins, Colo.
The University of Colorado Boulder (CU Boulder) is home to CU Cancer Center member Thomas Cech, PhD, who formed the Colorado Initiative in Molecular Biotechnology (CIMB). The CIMB brings together chemists, computer scientists, engineers, mathematicians, physicists, molecular and cellular biologists, and medical researchers to stimulate discoveries leading to novel diagnostics and therapeutics.
Translational opportunities in the CIMB are concentrated in five general areas: cancer, cardiovascular disease, inherited diseases including Down Syndrome, virology/vaccine development and regenerative medicine.
The CU Cancer Center also houses the Functional Genomics Shared Resource, which is lead by member Joaquin Espinosa, PhD. The Functional Genomics Shared Resource provides investigators with access to libraries of shRNAs that target every human and mouse gene along with advice and training on using these approaches.
CU Boulder's cancer researchers are CU Cancer Center members in the following research programs: Cancer Cell Biology, Developmental Therapeutics and Molecular Oncology. The Structural Biology Shared Resource's 800 MhZ spectrometer is located on the CU Boulder campus.
University of Colorado Boulder
Colorado Initiative in Molecular Biotechnology
The University of Colorado Cancer Center's central administrative and organizational structure is housed within the University of Colorado Denver (CU Denver). CU Denver consists of the downtown campus in Denver and the Anschutz Medical Campus in Aurora, where the CU Cancer Center administrative offices are located.
CU Denver provides a central authority to focus and organize our efforts and resources for the efficient and synergistic accomplishment of center goals.
The Colorado Multiple Institutional Review Board (COMIRB) located on both campuses provides office support for the five institutional review board (IRB) panels and processes protocols submitted for review under the expedited or exempt process. This board is used for all CU Cancer Center clinical protocols.
Also housed within the University of Colorado Denver is the Colorado Clinical and Translational Sciences Institute (CCTSI). In partnership with the CU Cancer Center, CCTSI co-funds and manages common Shared Resources; in turn reducing duplication and overhead while providing higher quality service for our members.
The CU Cancer Center is a major user of the enhanced clinical and translational infrastructure in the CCTSI's Clinical and Translational Research Centers (CTRCs), particularly for Phase I trials.
Additionally, the majority of the CU Cancer Center's Shared Resources and many of our members are from the health sciences schools and colleges are located on the University of Colorado Anschutz Medical Campus.
For adult patient care we refer patients to our partners at UCHealth. There are four UCHealth locations where a patient would receive care from a CU Cancer Center member, those are University of Colorado Hospital on the Anschutz Medical Campus, UCHealth Cherry Creek Medical Center, UCHealth Highlands Ranch Hospital and UCHealth Lone Tree Medical Center.
The University of Colorado Hospital (UCH) has been part of the of the University of Colorado Cancer Center since 1985. UCH constitutes the major academic partner of the CU Cancer Center and provides the majority of inpatient and outpatient services for adult patients of the CU Cancer Center.
UCH cancer physicians see nearly 100,000 outpatient cancer visits a year and its infusion center completed almost 18,000 procedures in the 2009-2010 fiscal year. The radiation oncology center saw more than 26,000 visits last year. These numbers explain why UCH expanded the Anschutz Cancer Pavilion in 2012, adding two radiation vaults and nearly doubling the number of infusion bays.
The hospital also houses a CU Cancer Center clinical trials program. The program had 1,110 people enrolled in therapeutic trials and nearly 9,000 people enrolled in prevention trials last year. Clinical research space at UCH has now grown to more than 12,000 square feet.
UCHealth Highlands Ranch Hospital opened in 2019. It is a full-service acute care hospital with over 100 in-patient beds, as well as an infusion center.
UCHealth Cherry Creek Medical Center opened in 2020. It provides outpatient cancer care services including an infusion center and radiation. It is an ambulatory surgery center, cancer care with infusion and radiation therapy, extensive outpatient lab services, and a pharmacy.
Through collaboration with the University of Colorado Cancer Center, the Denver Veterans Affairs Medical Center has seen a doubling of enrollments to therapeutic cancer trials in 2010 as well as an increase in enrollment to prevention trials.
Children’s Hospital Colorado has been ranked among the top pediatric oncology programs in the United States for more than 10 consecutive years by U.S. News and World Report. Children's Colorado physicians are national leaders in developing and executing clinical trials and linked correlative biology studies.
The pediatric neurooncology program is also nationally recognized, and Children's Colorado is the primary site of referral for children with brain cancer in the Rocky Mountain region. Through the development of one of the largest national pediatric brain tumor tissue banks, basic and translational cancer researchers have focused on the discovery of new prognostic markers and drug targets.
Children's Colorado's Experimental Therapeutics Program is the only program in the Rocky Mountain region that provides comprehensive early phase clinical trials for children with cancer. The Pediatric Oncology Experimental Therapeutics Investigators Consortium develops early phase clinical trials of targeted therapies that provide children and adolescents with refractory cancer with access to new treatments and modalities only available at a few highly select academic institutions around the country. The program was the first to open 12 different Phase I/II trials in the world, and first in the world to treat children in several different “First in Pediatric“ studies.
The majority of the research in pediatric oncology is translational in nature and carried out by physician-scientists who are divided among the CU Cancer Center Molecular Oncology and Developmental Therapeutic programs